FDA Approves Hemophilia B Second Gene Therapy.

Published Date: 29 Apr 2024

Standard prophylactic factor IX was found to be noninferior to one dose of fidanacogene elaparvovec.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer

2.

Atezolizumab + Cabozantinib Postpones mCRPC Progression.

3.

In advanced endometrial cancer, immunocheckpoint inhibitor-chemotherapy combination improves overall survival.

4.

Survey: Record Numbers of US Adults Report Depression.

5.

FDA Approves Hemophilia B Second Gene Therapy.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot